SARS-CoV InfectionPhase 2CloroCOVID19NCT04323527
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2
A Phase 2 study testing Chloroquine diphosphate in people with SARS-CoV Infection and Severe Acute Respiratory Syndrome (SARS) Pneumonia, run by Fundação de Medicina Tropical Dr. Heitor Vieira Dourado at 1 site in Brazil.
Trial summary
In December 2019, the Municipal Health Committee of Wuhan, China, identified an outbreak of viral pneumonia of unknown cause. This new coronavirus was called SARS-CoV-2 and the disease caused by that virus, COVID-19. Recent numbers show that 222,643 infections have been diagnosed with 9115 deaths, worldwide. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia
- What is being tested?
- Chloroquine diphosphate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 278 participants
- Where
- 1 siteBrazil
- Study dates
- 23 Mar 2020to 7 Jun 2020
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female participants aged over 18 years old
- Hospitalized
- presenting:
- respiratory rate higher than 24 breathing incursions per minute AND/OR
- heart rate higher than 125 beats per minute (in the absence of fever) AND/OR
- peripheral oxygen saturation lower than 90% in ambient air AND/OR
- shock (defined as mean arterial pressure less than 65 mmHg, requiring vasopressor or oliguria or lowering level of consciousness)
Who cannot join
- None.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz
Manaus, Amazonas, 69093-415
About this study
Official title: Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial
In December 2019, the Municipal Health Committee of Wuhan, China, identified an outbreak of viral pneumonia of unknown cause. This new coronavirus was called SARS-CoV-2 and the disease caused by that virus, COVID-19. Recent numbers show that 222,643 infections have been diagnosed with 9115 deaths, worldwide. Currently, there are no approved therapeutic agents available for coronaviruses. In this scenario, the situation of a global public health emergency and evidence about the potential positive effect of chloroquine (CQ) in most coronaviruses, including SARS-CoV-1, and recent data on small trials on SARS-CoV-2, the investigators intend to investigate the efficacy and the safety of CQ diphosphate in the treatment of hospitalized patients with severe acute respiratory syndrome in the scenario of SARS-CoV2. Preliminary in vitro studies and uncontrolled trials with low number of patients of CQ repositioning in the treatment of COVID-19 have been encouraging. The main hypothesis is that CQ diphosphate will reduce mortality in 50% in those with severe acute respiratory syndrome infected by the SARS-COV2. Therefore, the main objective is to assess whether the use of chloroquine diphosphate reduces mortality by 50% in the study population. The primary outcome is mortality in day 28 of follow-up. According to local contingency plan, developed by local government for COVID-19 in the State of Amazonas, the Hospital Pronto-Socorro Delphina Aziz, located in Manaus, is the reference unit for the admission of serious cases of the new virus. The unit currently has 50 ICU beds, with the possibility of expanding to 335 beds, if needed. The hospital also has trained multiprofessional human resources and adequate infrastructure. In total, 440 participants (220 per arm) will receive either high dose chloroquine 600 mg bid regime (4x150 mg tablets, every 12 hours, D1-D10) or low dose chloroquine 450mg bid regime (3x150mg tablets + 1 placebo tablet every 12 hours on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10). Placebo tablets were used to standardize treatment duration and blind research team and patients. All drugs administered orally (or via nasogastric tube in case of orotracheal intubation). Both intervention and placebo drugs will be produced by Farmanguinhos. Clinical and laboratory data during hospitalization will be used to assess efficacy and safety outcomes.
- Being tested
- Chloroquine diphosphate
- Keywords
- COVID-19, SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Chloroquine Diphosphate, Clinical trial
- Medical subject headings
- Severe Acute Respiratory Syndrome, Pneumonia, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chloroquine diphosphateDrug
Also called chloroquine
150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
| Study group | Role | What they receive |
|---|---|---|
| Low Dose Chloroquine Diphosphate (5 days) (Study stage 1) - Clorocovid 1 | Active comparator | Low dose chloroquine group consists of 450 mg bid (3 tablets of 150 mg + 1 placebo tablet, every 12 hours) on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10 . Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020). Receives: Drug: Chloroquine diphosphate |
| High Dose Chloroquine Diphosphate (10 days) (Study stage 1) - Clorocovid 1 | Active comparator | High dose chloroquine group consists of 600 mg bid (4 tablets of 150 mg, every 12 hours) for 10 days. Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020). Receives: Drug: Chloroquine diphosphate |
| Placebo (5 days) (Study stage 2) - Clorocovid 3 | Placebo comparator | Placebo group consists of 3 placebo tablets bid (day 1), and 3 placebo tablets once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020). Receives: Drug: Chloroquine diphosphate |
| Low Dose Chloroquine Diphosphate (5 days) (Study stage 2) - Clorocovid 3 | Active comparator | Low dose chloroquine group consisted of 450 mg bid (3 tablets of 150 mg) on D1, and 3x150mg tablet once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020). Receives: Drug: Chloroquine diphosphate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality rate reduction of 50% by day 28
proportion of deaths at day 28 between groups compared
Measured: 28 days after randomization
Secondary outcomes (15)
Absolute mortality on days 7 and 14
number of deaths at days 7 and 14 between groups compared
Measured: 7 and 14 days after first dose
Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28
clinical status
Measured: 14 and 28 days after first dose
Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization
clinical status
Measured: during and after intervention, up to 28 days
Duration of supplemental oxygen (if applicable)
supplemental oxygen
Measured: during and after intervention, up to 28 days
Duration of mechanical ventilation (if applicable)
mechanical ventilation
Measured: during and after intervention, up to 28 days
Absolute duration of hospital stay in days
hospitalization
Measured: during and after intervention, up to 28 days
Prevalence of grade 3 and 4 adverse events
adverse events grade 3 and 4
Measured: during and after intervention, up to 28 days
Prevalence of serious adverse events
adverse events
Measured: during and after intervention, up to 28 days
Change in serum creatinine level
increase or decrease in serum creatinine compared to baseline
Measured: during and after intervention, up to 28 days
Change in serum troponin I level
increase or decrease in serum troponin I compared to baseline
Measured: during and after intervention, up to 28 days
Change in serum aspartate aminotransferase level
increase or decrease in serum aspartate aminotransferase compared to baseline
Measured: during and after intervention, up to 28 days
Change in serum CK-MB level
increase or decrease in serum aspartate aminotransferase compared to baseline
Measured: during and after intervention, up to 28 days
Change in detectable viral load in respiratory tract swabs
virus clearance from respiratory tract secretion
Measured: during and after intervention, up to 28 days
Viral concentration in blood samples
viremia in blood detected through RT-PCR
Measured: during and after intervention, up to 28 days
Absolute number of causes leading to participant death (if applicable)
death
Measured: during and after intervention, up to 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2020
- Study start23 Mar 2020
- Primary completion7 May 2020
- Study completion7 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for SARS-CoV InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 278 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Sponsor type
- University, hospital or other
- Collaborators
- Marcus Vinícius Guimarães de Lacerda, Mayla Gabriela Silva Borba, Wuelton Marcelo Monteiro, Gisely Cardoso de Melo, Fernando Fonseca de Almeida e Val, Felipe Gomes Naveca, Maria Paula Gomes Mourão, Ludmila Abrahão Hajjar, Jorge Souza Mendonça
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04323527
- Sponsor's protocol ID
- CAAE: 30152620.1.0000.0005
- Acronym
- CloroCOVID19
- Status last verified
- Aug 2021
- First submitted
- 19 Mar 2020
- Last updated
- 9 Aug 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: all patient data will be shared after study publication
Publications
Erratum: Correlation between clinical and pathological findings of liver injury in 27 patients with lethal COVID-19 infections in Brazil. Hepatol Commun. 2024 Jun 27;8(7):e0492. doi: 10.1097/HC9.0000000000000492. eCollection 2024 Jul 1. No abstract available.
PubMed 38934714Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourao MPG, Brito-Sousa JD, Baia-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos JDO Jr, Naveca FG, Xavier MS, Siqueira AM, Schwarzbold A, Croda J, Nogueira ML, Romero GAS, Bassat Q, Fontes CJ, Albuquerque BC, Daniel-Ribeiro CT, Monteiro WM, Lacerda MVG; CloroCovid-19 Team. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
PubMed 32330277
Study at a glance
From the registry record, last updated by the sponsor on 9 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial
- ClinicalTrials.gov ID
- NCT04323527
- Acronym / sponsor ID
- CloroCOVID19 / CAAE: 30152620.1.0000.0005
- Keywords
- COVID-19, SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Chloroquine Diphosphate, Clinical trial
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 278 participants (actual)
- Lead sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira DouradoUniversity, hospital or other
- Collaborators
- Marcus Vinícius Guimarães de Lacerda, Mayla Gabriela Silva Borba, Wuelton Marcelo Monteiro, Gisely Cardoso de Melo, Fernando Fonseca de Almeida e Val, Felipe Gomes Naveca, Maria Paula Gomes Mourão, Ludmila Abrahão Hajjar, Jorge Souza Mendonça
- Study start
- 23 Mar 2020 (actual)
- Primary completion
- 7 May 2020 (actual)
- Study completion
- 7 Jun 2020 (actual)
- First posted
- 26 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In December 2019, the Municipal Health Committee of Wuhan, China, identified an outbreak of viral pneumonia of unknown cause. This new coronavirus was called SARS-CoV-2 and the disease caused by that virus, COVID-19. Recent numbers show that 222,643 infections have been diagnosed with 9115 deaths, worldwide. Currently, there are no approved therapeutic agents available for coronaviruses. In this scenario, the situation of a global public health emergency and evidence about the potential positive effect of chloroquine (CQ) in most coronaviruses, including SARS-CoV-1, and recent data on small trials on SARS-CoV-2, the investigators intend to investigate the efficacy and the safety of CQ diphosphate in the treatment of hospitalized patients with severe acute respiratory syndrome in the scenario of SARS-CoV2. Preliminary in vitro studies and uncontrolled trials with low number of patients of CQ repositioning in the treatment of COVID-19 have been encouraging. The main hypothesis is that CQ diphosphate will reduce mortality in 50% in those with severe acute respiratory syndrome infected by the SARS-COV2. Therefore, the main objective is to assess whether the use of chloroquine diphosphate reduces mortality by 50% in the study population. The primary outcome is mortality in day 28 of follow-up. According to local contingency plan, developed by local government for COVID-19 in the State of Amazonas, the Hospital Pronto-Socorro Delphina Aziz, located in Manaus, is the reference unit for the admission of serious cases of the new virus. The unit currently has 50 ICU beds, with the possibility of expanding to 335 beds, if needed. The hospital also has trained multiprofessional human resources and adequate infrastructure. In total, 440 participants (220 per arm) will receive either high dose chloroquine 600 mg bid regime (4x150 mg tablets, every 12 hours, D1-D10) or low dose chloroquine 450mg bid regime (3x150mg tablets + 1 placebo tablet every 12 hours on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10). Placebo tablets were used to standardize treatment duration and blind research team and patients. All drugs administered orally (or via nasogastric tube in case of orotracheal intubation). Both intervention and placebo drugs will be produced by Farmanguinhos. Clinical and laboratory data during hospitalization will be used to assess efficacy and safety outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Low Dose Chloroquine Diphosphate (5 days) (Study stage 1) - Clorocovid 1 | Active comparator | Drug: Chloroquine diphosphateLow dose chloroquine group consists of 450 mg bid (3 tablets of 150 mg + 1 placebo tablet, every 12 hours) on D1, 3x150mg tablets + 1 placebo followed by 4 placebo tablets 12h later from D2 to D5, and 4 placebo tablets every 12 hours, D6-D10 . Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020). |
| High Dose Chloroquine Diphosphate (10 days) (Study stage 1) - Clorocovid 1 | Active comparator | Drug: Chloroquine diphosphateHigh dose chloroquine group consists of 600 mg bid (4 tablets of 150 mg, every 12 hours) for 10 days. Oral administration or via nasogastric tube in case of orotracheal intubation. (this was the first stage of the original study and was approved by the Brazilian IRB on 23/March/2020). |
| Placebo (5 days) (Study stage 2) - Clorocovid 3 | Placebo comparator | Drug: Chloroquine diphosphatePlacebo group consists of 3 placebo tablets bid (day 1), and 3 placebo tablets once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020). |
| Low Dose Chloroquine Diphosphate (5 days) (Study stage 2) - Clorocovid 3 | Active comparator | Drug: Chloroquine diphosphateLow dose chloroquine group consisted of 450 mg bid (3 tablets of 150 mg) on D1, and 3x150mg tablet once daily from D2 to D5. Oral administration or via a nasogastric tube in case of orotracheal intubation. (this was a second stage of the original study and was approved by the Brazilian IRB on 03/May/2020). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Male and female participants aged over 18 years old
- Hospitalized
- presenting:
Key exclusion criteria (1 listed)
- None.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chloroquine diphosphateAlso: chloroquine150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg). | Drug | High Dose Chloroquine Diphosphate (10 days) (Study stage 1) - Clorocovid 1, Low Dose Chloroquine Diphosphate (5 days) (Study stage 1) - Clorocovid 1, Low Dose Chloroquine Diphosphate (5 days) (Study stage 2) - Clorocovid 3, Placebo (5 days) (Study stage 2) - Clorocovid 3 |
Primary outcome
Mortality rate reduction of 50% by day 28
Time frame: 28 days after randomization
proportion of deaths at day 28 between groups compared
15 secondary outcomes
Absolute mortality on days 7 and 14
Time frame: 7 and 14 days after first dose
Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28
Time frame: 14 and 28 days after first dose
Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization
Time frame: during and after intervention, up to 28 days
Duration of supplemental oxygen (if applicable)
Time frame: during and after intervention, up to 28 days
Duration of mechanical ventilation (if applicable)
Time frame: during and after intervention, up to 28 days
Absolute duration of hospital stay in days
Time frame: during and after intervention, up to 28 days
Prevalence of grade 3 and 4 adverse events
Time frame: during and after intervention, up to 28 days
Prevalence of serious adverse events
Time frame: during and after intervention, up to 28 days
Change in serum creatinine level
Time frame: during and after intervention, up to 28 days
Change in serum troponin I level
Time frame: during and after intervention, up to 28 days
Change in serum aspartate aminotransferase level
Time frame: during and after intervention, up to 28 days
Change in serum CK-MB level
Time frame: during and after intervention, up to 28 days
Change in detectable viral load in respiratory tract swabs
Time frame: during and after intervention, up to 28 days
Viral concentration in blood samples
Time frame: during and after intervention, up to 28 days
Absolute number of causes leading to participant death (if applicable)
Time frame: during and after intervention, up to 28 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Aug 2021.
- Derived from this study: PubMed 38934714Erratum: Correlation between clinical and pathological findings of liver injury in 27 patients with lethal COVID-19 infections in Brazil. Hepatol Commun. 2024 Jun 27;8(7):e0492. doi: 10.1097/HC9.0000000000000492. eCollection 2024 Jul 1. No abstract available.
- Derived from this study: PubMed 32330277Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourao MPG, Brito-Sousa JD, Baia-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro AAS, Pacheco AGF, Santos JDO Jr, Naveca FG, Xavier MS, Siqueira AM, Schwarzbold A, Croda J, Nogueira ML, Romero GAS, Bassat Q, Fontes CJ, Albuquerque BC, Daniel-Ribeiro CT, Monteiro WM, Lacerda MVG; CloroCovid-19 Team. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
- Individual participant dataSharing planned: Yes. all patient data will be shared after study publication
Related trials for SARS-CoV Infection
RecruitingPhase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Respiratory Tract Diseases, Influenza (Pandemic)
Not yet recruiting
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
Respiratory Viral Infections, Influenza
Recruiting
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
COVID-19, Long COVID
Active, not recruiting
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
SARS-CoV Infection
Active, not recruiting
Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-Counter (OTC) Use in Australia
SARS CoV 2 Infection, Influenza A Virus Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Chloroquine diphosphate in people with SARS-CoV Infection and Severe Acute Respiratory Syndrome (SARS) Pneumonia, run by Fundação de Medicina Tropical Dr. Heitor Vieira Dourado at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality rate reduction of 50% by day 28 (time frame: 28 days after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04323527, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2021.